A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Study ID
NCT07714668
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.

Key Dates

First listed
Jul 20, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2028
Completion
Aug 31, 2029

Study Design

Enrollment
171 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SYS6041, bevacizumab
  • Experimental: SYS6041, carboplatin, bevacizumab
  • Active Comparator: paclitaxel, carboplatin, bevacizumab
  • Active Comparator: SYS6041, enlonstobart, bevacizumab

Primary Outcome Measure

The incidence of dose-limiting toxicity (DLT) [ Time Frame: At the end of Cycle 1 (each cycle is 21 days) ]

Central Contacts

Find similar trials

Nationwide
Ovarian cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies